© 2017 Evestra, Inc.

Research Pipeline

In conducting its research and development activities in support of its women’s health product initiatives, Evestra has, over its history, identified product opportunities deriving from its core platform technologies that appear to have significant potential but which are outside of the scope of its women’s health focus. 

The Company is seeking to license these potential products to partners which have important franchises in these therapeutic areas.

EC625 is an injectable fertility control product that will provide protection for up to six (6) months. It has the potential to be significantly superior to the market leader, Depot Provera®, based on targeted longer activity and fewer anticipated side effects. The project is supported by the Gates Foundation.

EC508 is a prodrug of the natural estrogen, estradiol. This compound exhibits high oral bioavailability and no sign of hepatic estrogenicity in rats. This product can form the basis for a new generation of oral fertility control with a lower risk of deep-vein thrombosis compared to the currently marketed products.

EC317 is a progesterone receptor antagonist that has, in preclinical studies in animal models, shown superiority over market products as a postcoital fertility control product and can be used to soften the cervix at term.

EC313 is a partial agonistic antiprogestin for the treatment of heavy menstrual bleeding, fibroids and endometriosis. EC313 has potential advantages over other antiprogestins on the market (or under development) by avoiding any abortive potential and the unlimited duration treatment under which the product can be administered. Evestra received a $4.6 million grant from EU through Evestra’s Polish subsidiary for the development of EC313 for endometriosis.

http://www.mdpi.com/genes/genes-02-00280/article_deploy/html/images/genes-02-00280f1-1024.png

EC359 Leukemia Inhibitory Factor (LIF) Antagonist. Evestra's R&D team is working on advancing an innovative pipeline in oncology.  Evestra's innovative oncology pipeline is led by EC359 LIF antagonist which has been demonstrated to inhibit a wide range of tumor types including NSCLC, breast, ovarian, colon and pancreatic, including tumors resistant to standard-of-care therapies

Project Code

Classification

Target Disease

Phase/ Next Milestones

Dosage Form

Remarks

Fertility Control (FC) & Hormone Replacement Therapy (HRT)

EC625

6-month Injectable contraceptive

FC

IND Q3/2018

Injectable

Fewer side effects and longer duration

EC508

Estradiol prodrug with high bioavailability

HRT/FC

IND Q2/2018

Oral

Basis for a new generation of oral contraceptives

EC317

Postcoital fertility  control

FC

IND Q3/2018

Oral

Higher efficacy than Plan B

Uterine Fibroids and endometriosis

EC313

Partial agonist antiprogestin

Fibroids & Endometriosis

IND Q4/2018

Oral

$4.6 million grant from EU

Others

EC359

Leukemia Inhibitory Factor (LIF) Antagonist

Pancreatic & Breast Cancer

IND Q4/2018

Oral

First in class

EC586

Testosterone prodrug

Male HRT

IND Q4/2018

Oral

Comparable efficacy to Testoderm®